Editorial: how widespread and serious is non-alcoholic fatty liver disease in the real world? Authors' reply
Aliment Pharmacol Ther
.
2020 Jun;51(11):1200-1201.
doi: 10.1111/apt.15724.
Authors
Rohit Loomba
1
2
,
Robert Wong
3
,
Jeremy Fraysse
4
,
Sanatan Shreay
4
,
Suying Li
5
,
Stephen Harrison
6
,
Stuart C Gordon
7
Affiliations
1
Department of Medicine, NAFLD Research Center, La Jolla, CA, USA.
2
Division of Gastroenterology, Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
3
Division of Gastroenterology and Hepatology, Alameda Health System, Highland Hospital, Oakland, CA, USA.
4
Health Economics Outcomes Research, Gilead Sciences, Foster City, CA, USA.
5
Chronic Disease Research Group, Minneapolis, MN, USA.
6
Pinnacle Clinical Research, San Antonio, TX, USA.
7
Department of Gastroenterology and Hepatology, Henry Ford Hospital, Wayne State University School of Medicine, Detroit, MI, USA.
PMID:
32424927
DOI:
10.1111/apt.15724
No abstract available
Publication types
Editorial
Comment
MeSH terms
Aged
Disease Progression
Fibrosis
Humans
Liver Cirrhosis
Medicare
Non-alcoholic Fatty Liver Disease*
United States